Biogen virtual symposium

EAN 2021

On June 19 and 20, world-leading neuromuscular experts participated in two virtual symposia at the 7th Annual Meeting of the European Academy of Neurology. Here’s a recap of the event:

The characters shown are real patients and the required consent to use their stories has been obtained from the patients and families. Photographs are for illustrative purposes only.


Over the course of two connected symposia, neuromuscular experts discussed the latest SMA evidence and shared their perspectives on what  this means for treating adults with SMA.

Symposium 1: To treat or not to treat

Using real-life cases studies of adult patients with SMA, Dr. Konersman and Dr. Kostera-Pruszczyk examined the challenges of treatment access and outcome expectations.​

Symposium 2: How to define the treatment response

In the second symposium, the doctors considered approaches in defining response to treatment for adults with SMA, reviewing two case studies from their respective clinics.

Meet the faculty

Chamindra Konersman


University of California San Diego (UCSD) and Rody Children’s Hospital, San Diego, CA, USA

Anna Kostera-Pruszczyk


Central Clinical Hospital University Clinical Center of the Medical University of Warsaw, Warsaw, Poland

More Resources about SMA for Healthcare Professionals

Stabilisation of motor function is an important goal for adults living with SMA.1 Learn more about the differences in treatment goals between adults and children living with SMA.

Now that supportive care is improving, care expectations are even greater. Explore Biogen’s website to learn how discussing new care options with your patients can make a difference.

Stay up to date

Learn more about Biogen's participation in
ICNMD and Neurology events.

Check out the Biogen-sponsored symposia, publications and posters about SMA from this and other past congresses at: SMA scientific lounge


1. 1. Rouault F, et al. Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients. Neuromuscul Disord 2017;27(5):428-438.